Study guide

3.2 Immunology

NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the FPGEE 1.2 How to Use This Study Guide

2 Chapter 2: Foundational Biomedical Sciences I

2.1 Anatomy 2.2 Physiology 2.3 Biochemistry

3 Chapter 3: Foundational Biomedical Sciences II

3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases

4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry

4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions

5 Chapter 5: Pharmacology and Toxicology

5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes

6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics

6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics

7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems

7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics

8 Chapter 8: Public Health, Practice Management, and Biostatistics

8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods

9 Chapter 9: Professional Communication and Behavioral Aspects

9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice

10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment

10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education

11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care

11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine

12 Chapter 12: Clinical Sciences III — Evidence-Based Practice

12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability

13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products

13.1 Self-Care and Natural Products

3.2 Immunology

Key Takeaways Explain This Topic AI

Innate immunity acts within minutes using physical barriers, complement, phagocytes, NK cells, and pattern-recognition receptors such as TLR4 (LPS) and TLR3 (double-stranded RNA).

Adaptive immunity provides antigen-specific memory: B cells produce antibodies (humoral), CD4 helper T cells coordinate responses, and CD8 cytotoxic T cells kill infected cells through perforin and granzymes.

MHC class I presents intracellular peptides to CD8 T cells on all nucleated cells; MHC class II presents extracellular peptides to CD4 T cells on professional antigen-presenting cells.

The five antibody classes are IgG (most abundant, crosses placenta), IgM (first produced, pentamer), IgA (mucosal immunity), IgE (allergy and parasites), and IgD (B-cell receptor).

Calcineurin inhibitors cyclosporine and tacrolimus block IL-2 transcription and T-cell activation, making live-attenuated vaccines contraindicated during therapy.

Last updated: July 2026

The immune system distinguishes self from non-self through two cooperating arms: the innate (rapid, nonspecific) and adaptive (slow, specific, memory-bearing) responses. The NABP FPGEE Content Outline expects you to apply these concepts to vaccination, hypersensitivity, transplantation, and immunosuppressive therapy.

Innate Immunity

Innate defenses act within minutes. Physical barriers (skin, mucociliary escalator, gastric pH) block entry. Pattern-recognition receptors such as the Toll-like receptors (TLRs) detect conserved pathogen-associated molecular patterns (PAMPs): TLR4 recognizes LPS, TLR3 recognizes double-stranded RNA, and TLR2 recognizes gram-positive lipoteichoic acid. Complement cascades (classical, alternative, and lectin pathways) opsonize pathogens, recruit neutrophils via C5a, and form the membrane attack complex (C5b through C9). Phagocytes — neutrophils (first responders, short-lived) and macrophages (tissue-resident, antigen-presenting) — engulf and kill via the respiratory burst and lysosomal enzymes. Natural killer (NK) cells kill virus-infected and tumor cells that downregulate MHC class I. The classic inflammatory signs — rubor, tumor, calor, dolor — describe the vascular and cellular response to injury.

Adaptive Immunity

Adaptive responses are antigen-specific and show memory. B lymphocytes mediate humoral immunity by differentiating into plasma cells that secrete antibodies. T lymphocytes mediate cell-mediated immunity . CD4 helper T cells coordinate responses via cytokines; CD8 cytotoxic T cells kill infected cells using perforin and granzymes.

Antigen presentation uses major histocompatibility complex (MHC) molecules. MHC class I presents intracellular peptides (viral, tumor) to CD8 T cells and is expressed on all nucleated cells. MHC class II presents extracellular peptides to CD4 T cells and is restricted to professional antigen-presenting cells (dendritic cells, macrophages, B cells).

Antibody Classes

Class Structure Primary Function

IgG Monomer, crosses placenta Most abundant serum antibody; opsonization, complement activation, secondary response

  • IgM Pentamer First antibody produced in a primary response; potent complement activator
  • IgA Dimer with secretory component Mucosal and secretory immunity
  • IgE Monomer Binds mast cells and basophils; mediates allergy and parasite defense
  • IgD Monomer Surface receptor on naive B cells
  • Hypersensitivity Reactions
  • Type Mechanism Drug or Disease Example
  • I — Immediate (IgE) IgE cross-links mast cells, releasing histamine Penicillin anaphylaxis, allergic rhinitis

II — Cytotoxic (IgG or IgM) Antibody binds cell surface, triggers complement or ADCC Heparin-induced thrombocytopenia, hemolytic transfusion reaction

III — Immune complex Antigen-antibody deposits activate complement Serum sickness, lupus nephritis

IV — Delayed (T cell) T-cell-mediated macrophage activation Contact dermatitis from poison ivy, PPD reaction, type 1 diabetes

Autoimmunity

Autoimmune disease arises when self-tolerance fails. Systemic lupus erythematosus (SLE) features antinuclear antibodies and immune-complex deposition in kidneys and skin. Rheumatoid arthritis targets the synovium with anti-cyclic citrullinated peptide (anti-CCP) antibodies. Type 1 diabetes destroys pancreatic beta cells through a Type IV mechanism. Hashimoto's thyroiditis causes hypothyroidism via anti-thyroid peroxidase antibodies.

Immunization

Active immunity results from natural infection or vaccination and produces immunologic memory. Passive immunity transfers preformed antibodies (maternal IgG, rabies immune globulin, IVIG) and is short-lived. Vaccine types include live-attenuated (MMR, varicella, LAIV, yellow fever — contraindicated in significant immunocompromise), inactivated (IPV, rabies), subunit and recombinant (hepatitis B, HPV), toxoid (tetanus, diphtheria), and mRNA (COVID-19).

Cytokines and Immune Signaling

Cytokines are the chemical messengers that coordinate immune responses. Pro-inflammatory cytokines — IL-1, IL-6, and TNF-alpha — drive fever, acute-phase reactant synthesis (CRP, ferritin, fibrinogen), and systemic inflammation. IL-2 expands T cells after antigen recognition. IL-4 and IL-5 promote IgE class switching and eosinophil activation in allergy and parasite defense. IL-12 drives Th1 responses (intracellular pathogens), while IL-17 (from Th17 cells) recruits neutrophils for extracellular bacterial and fungal defense. Interferon-alpha inhibits viral replication; interferon-gamma activates macrophages. Therapeutic cytokine blockade has transformed autoimmune treatment: anti-TNF agents (infliximab, adalimumab, etanercept) treat rheumatoid arthritis, psoriasis, and inflammatory bowel disease but raise infection risk (reactivation of latent TB, fungal pneumonia). IL-6 blockade (tocilizumab) is used in giant cell arteritis and RA. IL-17 blockade (secukinumab) treats psoriasis and ankylosing spondylitis but can flare inflammatory bowel disease.

Immunodeficiency and Transplantation

Primary immunodeficiencies are rare inherited defects: X-linked agammaglobulinemia (absent B cells), common variable immunodeficiency (low antibody production), severe combined immunodeficiency (SCID) (defective T and B cells — fatal without bone marrow transplant), DiGeorge syndrome (thymic aplasia → T-cell deficiency), Wiskott-Aldrich (B and T cells with eczema and thrombocytopenia). Secondary immunodeficiency is far more common: HIV/AIDS (CD4 depletion), immunosuppressive drugs, malignancy, malnutrition, and splenectomy (encapsulated organism risk — vaccinate against pneumococcus, meningococcus, and H. influenzae b).

Transplantation matches donor and recipient through HLA typing and ABO compatibility . Solid organ transplants require lifelong immunosuppression, typically a calcineurin inhibitor plus an antimetabolite plus a corticosteroid . Hematopoietic stem cell transplantation carries graft-versus-host disease (GVHD) risk because donor T cells attack host tissues; prophylaxis uses methotrexate plus a calcineurin inhibitor. Rejection episodes are treated with high-dose corticosteroids, anti-thymocyte globulin, or plasmapheresis (antibody-mediated rejection).

Immunosuppressants

Cyclosporine and tacrolimus — calcineurin inhibitors; block IL-2 transcription and T-cell activation. Monitor tacrolimus trough 5-15 ng/mL; nephrotoxicity and hypertension are shared adverse effects. Cyclosporine also causes gingival hyperplasia and hirsutism.

Sirolimus (rapamycin) — mTOR inhibitor; blocks T-cell proliferation downstream of IL-2. Causes hyperlipidemia, impaired wound healing, and interstitial pneumonitis.

Corticosteroids — suppress NF-kB-driven cytokine production and T-cell proliferation.

Azathioprine — purine analog that blocks lymphocyte DNA synthesis.

Mycophenolate — inhibits inosine monophosphate dehydrogenase, on which lymphocytes are especially dependent.

Basiliximab — anti-CD25 monoclonal antibody for induction therapy.

Rituximab — anti-CD20 monoclonal antibody that depletes B cells.

Loading diagram...

Loading diagram... Innate and Adaptive Immunity Cascade